In a statement to the press, Dr. Frederick L. Hall, President and CEO of Epeius, stated "Whereas logistics had previously stymied the delivery of genetic medicine to target lesions within the human body, intravenous infusions of Rexin-G has stymied intractable cancers without collateral damage to normal organs." The results, compiled in these pioneering studies, had convinced the US FDA to grant Rexin-G orphan drug status for pancreatic cancer, and subsequently, to provide federal support to continue clinical trials using Rexin-G in the United States. Further, based on these studies, the Philippine Bureau of Food and Drugs recently granted Rexin-G accelerated marketing approval for the treatment of all chemotherapy-resistant tumor types.
About Epeius Biotechnologies
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. Credited with innovations ranging from oncogene discovery, to designer-gene therapy, to pathotropic (disease-seeking) targeting, to high-performance vector engineering, to advanced GMP and bioprocess development, Epeius Biotechnologies is well positioned to "launch" its enabling platform technologies for the benefit of cancer patients worldwide. To learn more about Rexin-G and Epeius' pipeline of proprietary therapeutics currently available for partnership, please visit us at
http://www.epeiusbiotech.com.
This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R).
http://www.Send2Press.com.
Epeius Biotechnologies
http://www.epeiusbiotech.com